HBM Healthcare Investments Ltd

Latest Results (14.10.2025):

HBM Healthcare Investments Ltd reported strong financial results for the second quarter of the 2025/2026 financial year. The company achieved a 16.4% increase in net asset value (NAV) per share, reaching CHF 251.78, and recorded a quarterly profit of CHF 236 million, effectively offsetting the currency-related losses from the first quarter.

Net Asset Value Growth

In the second quarter of the 2025/2026 financial year, HBM Healthcare Investments Ltd increased its NAV per share by 16.4%, reaching CHF 251.78. This substantial growth highlights the company's effective investment strategies and portfolio performance.

Quarterly Profit Achievement

The company reported a quarterly profit of CHF 236 million, which successfully offset the primarily currency-related losses incurred in the first quarter. This profit underscores HBM Healthcare Investments Ltd's robust financial health and operational efficiency.

Portfolio Performance

The positive second-quarter results were driven by renewed momentum among HBM Healthcare Investments Ltd's listed portfolio companies. Significant contributions came from positive clinical trial outcomes for Abivax, Mineralys, Upstream Bio, and UniQure, along with takeover bids for Merus, Y-mAbs Therapeutics, and 89Bio.

Currency Impact

Foreign currencies had no significant impact on the second-quarter performance. However, in the first three months of the financial year, currency fluctuations adversely affected the portfolio, reducing performance by 8.9% in reporting currency terms.

Outlook for the Second Half

HBM Healthcare Investments Ltd remains optimistic about the second half of the financial year, anticipating further positive momentum from its investments in both private and listed companies. The company expects continued operational progress and strategic transactions despite an uncertain market environment.